{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:59:45Z","timestamp":1792162785944,"version":"4.4.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Natural Science Foundation of Guangxi","award":["2020GXNSFAA159050"],"award-info":[{"award-number":["2020GXNSFAA159050"]}]},{"name":"Natural Science Foundation of Guangxi","award":["2021GXNSFDA075002"],"award-info":[{"award-number":["2021GXNSFDA075002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nonalcoholic steatohepatitis (NASH) is an advanced form of chronic fatty liver disease, which is a driver of hepatocellular carcinoma. However, the roles of the C5aR1 in the NASH remain poorly understood. Here, we aimed to investigate the functions and mechanisms of the C5aR1 on hepatic inflammation and fibrosis in murine NASH model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Mice were fed a normal chow diet with corn oil (ND\u2009+\u2009Oil), a Western diet with corn oil (WD\u2009+\u2009Oil) or a Western diet with carbon tetrachloride (WD\u2009+\u2009CCl\n                      <jats:sub>4<\/jats:sub>\n                      ) for 12\u00a0weeks. The effects of the C5a\u2013C5aR1 axis on the progression of NASH were analyzed and the underlying mechanisms were explored.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Complement factor C5a was elevated in NASH mice. C5 deficiency reduced hepatic lipid droplet accumulation in the NASH mice. The hepatic expression levels of TNF\u03b1, IL-1\u03b2 and F4\/80 were decreased in C5-deficient mice. C5 loss alleviated hepatic fibrosis and downregulated the expression levels of \u03b1-SMA and TGF\u03b21. C5aR1 deletion reduced inflammation and fibrosis in NASH mice. Transcriptional profiling of liver tissues and KEGG pathway analysis revealed that several pathways such as Toll-like receptor signaling, NF\u03baB signaling, TNF signaling, and NOD-like receptor signaling pathway were enriched between C5aR1 deficiency and wild-type mice. Mechanistically, C5aR1 deletion decreased the expression of TLR4 and NLRP3, subsequently regulating macrophage polarization. Moreover, C5aR1 antagonist PMX-53 treatment mitigated the progression of NASH in mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Blockade of the C5a\u2013C5aR1 axis reduces hepatic steatosis, inflammation, and fibrosis in NASH mice. Our data suggest that C5aR1 may be a potential target for drug development and therapeutic intervention of NASH.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00535-023-02002-w","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T01:01:38Z","timestamp":1684976498000},"page":"894-907","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Blockade of C5aR1 alleviates liver inflammation and fibrosis in a mouse model of NASH by regulating TLR4 signaling and macrophage polarization"],"prefix":"10.1007","volume":"58","author":[{"given":"Keqing","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sifan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songqing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2606-1285","authenticated-orcid":false,"given":"Fudi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"2002_CR1","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397:2212\u201324.","journal-title":"Lancet"},{"key":"2002_CR2","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1002\/hep.26986","volume":"59","author":"RJ Wong","year":"2014","unstructured":"Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology. 2014;59:2188\u201395.","journal-title":"Hepatology"},{"key":"2002_CR3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","volume":"148","author":"RJ Wong","year":"2015","unstructured":"Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547\u201355.","journal-title":"Gastroenterology"},{"key":"2002_CR4","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s00535-021-01833-9","volume":"56","author":"Y Kamada","year":"2021","unstructured":"Kamada Y, Takahashi H, Shimizu M, et al. Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review. J Gastroenterol. 2021;56:1045\u201361.","journal-title":"J Gastroenterol"},{"key":"2002_CR5","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00535-021-01796-x","volume":"56","author":"K Tokushige","year":"2021","unstructured":"Tokushige K, Ikejima K, Ono M, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020. J Gastroenterol. 2021;56:951\u201363.","journal-title":"J Gastroenterol"},{"key":"2002_CR6","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/hepr.13688","volume":"51","author":"K Tokushige","year":"2021","unstructured":"Tokushige K, Ikejima K, Ono M, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020. Hepatol Res Off J Japan Soc Hepatol. 2021;51:1013\u201325.","journal-title":"Hepatol Res Off J Japan Soc Hepatol"},{"key":"2002_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.freeradbiomed.2011.10.003","volume":"52","author":"AP Rolo","year":"2012","unstructured":"Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radical Biol Med. 2012;52:59\u201369.","journal-title":"Free Radical Biol Med"},{"issue":"133\u201345","key":"2002_CR8","first-page":"e15","volume":"175","author":"JY Kim","year":"2018","unstructured":"Kim JY, Garcia-Carbonell R, Yamachika S, et al. ER Stress Drives Lipogenesis and Steatohepatitis via Caspase-2 Activation of S1P. Cell. 2018;175(133\u201345):e15.","journal-title":"Cell"},{"key":"2002_CR9","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1007\/s10620-016-4049-x","volume":"61","author":"M Arrese","year":"2016","unstructured":"Arrese M, Cabrera D, Kalergis AM, et al. Innate Immunity and Inflammation in NAFLD\/NASH. Dig Dis Sci. 2016;61:1294\u2013303.","journal-title":"Dig Dis Sci"},{"key":"2002_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.smim.2013.04.003","volume":"25","author":"J Phieler","year":"2013","unstructured":"Phieler J, Garcia-Martin R, Lambris JD, et al. The role of the complement system in metabolic organs and metabolic diseases. Semin Immunol. 2013;25:47\u201353.","journal-title":"Semin Immunol"},{"key":"2002_CR11","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1002\/hep.23228","volume":"50","author":"SS Rensen","year":"2009","unstructured":"Rensen SS, Slaats Y, Driessen A, et al. Activation of the complement system in human Nonalcoholic Fatty liver disease. Hepatology. 2009;50:1809\u201317.","journal-title":"Hepatology"},{"key":"2002_CR12","doi-asserted-by":"publisher","first-page":"23279","DOI":"10.1038\/srep23279","volume":"6","author":"C Xu","year":"2016","unstructured":"Xu C, Chen Y, Xu L, et al. Serum complement C3 levels are associated with nonalcoholic fatty liver disease independently of metabolic features in Chinese population. Sci Rep. 2016;6:23279.","journal-title":"Sci Rep"},{"key":"2002_CR13","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/apa.14106","volume":"107","author":"W Hu","year":"2018","unstructured":"Hu W, Wang M, Yin C, et al. Serum complement factor 5a levels are associated with nonalcoholic fatty liver disease in obese children. Acta Paediatr. 2018;107:322\u20137.","journal-title":"Acta Paediatr"},{"key":"2002_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.imlet.2016.07.014","volume":"177","author":"L Bavia","year":"2016","unstructured":"Bavia L, Cogliati B, Dettoni JB, et al. The complement component C5 promotes liver steatosis and inflammation in murine non-alcoholic liver disease model. Immunol Lett. 2016;177:53\u201361.","journal-title":"Immunol Lett"},{"key":"2002_CR15","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.imbio.2016.01.014","volume":"221","author":"L Bavia","year":"2016","unstructured":"Bavia L, de Castro IA, Cogliati B, et al. Complement C5 controls liver lipid profile, promotes liver homeostasis and inflammation in C57BL\/6 genetic background. Immunobiology. 2016;221:822\u201332.","journal-title":"Immunobiology"},{"key":"2002_CR16","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/ng1599","volume":"37","author":"S Hillebrandt","year":"2005","unstructured":"Hillebrandt S, Wasmuth HE, Weiskirchen R, et al. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet. 2005;37:835\u201343.","journal-title":"Nat Genet"},{"key":"2002_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/imm.12024","volume":"138","author":"R Xu","year":"2013","unstructured":"Xu R, Lin F, He J, et al. Complement 5a stimulates hepatic stellate cells in vitro, and is increased in the plasma of patients with chronic hepatitis B. Immunology. 2013;138:228\u201334.","journal-title":"Immunology"},{"key":"2002_CR18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.bbrc.2012.01.036","volume":"418","author":"J Schmitt","year":"2012","unstructured":"Schmitt J, Roderfeld M, Sabrane K, et al. Complement factor C5 deficiency significantly delays the progression of biliary fibrosis in bile duct-ligated mice. Biochem Biophys Res Commun. 2012;418:445\u201350.","journal-title":"Biochem Biophys Res Commun"},{"key":"2002_CR19","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.kint.2016.04.023","volume":"90","author":"N Choudhry","year":"2016","unstructured":"Choudhry N, Li K, Zhang T, et al. The complement factor 5a receptor 1 has a pathogenic role in chronic inflammation and renal fibrosis in a murine model of chronic pyelonephritis. Kidney Int. 2016;90:540\u201354.","journal-title":"Kidney Int"},{"key":"2002_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.kint.2019.01.039","volume":"96","author":"Q Peng","year":"2019","unstructured":"Peng Q, Wu W, Wu KY, et al. The C5a\/C5aR1 axis promotes progression of renal tubulointerstitial fibrosis in a mouse model of renal ischemia\/reperfusion injury. Kidney Int. 2019;96:117\u201328.","journal-title":"Kidney Int"},{"key":"2002_CR21","doi-asserted-by":"publisher","first-page":"G825","DOI":"10.1152\/ajpgi.00145.2011","volume":"301","author":"M Charlton","year":"2011","unstructured":"Charlton M, Krishnan A, Viker K, et al. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol. 2011;301:G825\u201334.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2002_CR22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jhep.2018.03.011","volume":"69","author":"T Tsuchida","year":"2018","unstructured":"Tsuchida T, Lee YA, Fujiwara N, et al. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J Hepatol. 2018;69:385\u201395.","journal-title":"J Hepatol"},{"key":"2002_CR23","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.2147\/JIR.S343236","volume":"15","author":"M Saha","year":"2022","unstructured":"Saha M, Manna K, Das SK. Melatonin suppresses NLRP3 inflammasome activation via TLR4\/NF-kappaB and P2X7R signaling in high-fat diet-induced Murine NASH model. J Inflamm Res. 2022;15:3235\u201358.","journal-title":"J Inflamm Res"},{"issue":"17","key":"2002_CR24","doi-asserted-by":"publisher","first-page":"9954","DOI":"10.3390\/ijms23179954","volume":"23","author":"EE Vargas-Pozada","year":"2022","unstructured":"Vargas-Pozada EE, Ramos-Tovar E, Rodriguez-Callejas JD, et al. Caffeine inhibits NLRP3 inflammasome activation by downregulating TLR4\/MAPK\/NF-kappaB signaling pathway in an experimental NASH model. Int J Mole Sci. 2022;23(17):9954.","journal-title":"Int J Mole Sci"},{"key":"2002_CR25","doi-asserted-by":"publisher","first-page":"101634","DOI":"10.1016\/j.redox.2020.101634","volume":"36","author":"F Xu","year":"2020","unstructured":"Xu F, Guo M, Huang W, et al. Annexin A5 regulates hepatic macrophage polarization via directly targeting PKM2 and ameliorates NASH. Redox Biol. 2020;36:101634.","journal-title":"Redox Biol"},{"key":"2002_CR26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/hep.26607","volume":"59","author":"J Wan","year":"2014","unstructured":"Wan J, Benkdane M, Teixeira-Clerc F, et al. M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology. 2014;59:130\u201342.","journal-title":"Hepatology"},{"key":"2002_CR27","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.2337\/db11-1595","volume":"61","author":"JS Orr","year":"2012","unstructured":"Orr JS, Puglisi MJ, Ellacott KL, et al. Toll-like receptor 4 deficiency promotes the alternative activation of adipose tissue macrophages. Diabetes. 2012;61:2718\u201327.","journal-title":"Diabetes"},{"key":"2002_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cmet.2011.06.002","volume":"14","author":"JL Yecies","year":"2011","unstructured":"Yecies JL, Zhang HH, Menon S, et al. Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab. 2011;14:21\u201332.","journal-title":"Cell Metab"},{"key":"2002_CR29","first-page":"73","volume":"4","author":"JV Sarma","year":"2012","unstructured":"Sarma JV, Ward PA. New developments in C5a receptor signaling. Cell Health Cytoskeleton. 2012;4:73\u201382.","journal-title":"Cell Health Cytoskeleton"},{"key":"2002_CR30","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.clim.2013.11.014","volume":"150","author":"M Vasel","year":"2014","unstructured":"Vasel M, Rutz R, Bersch C, et al. Complement activation correlates with liver necrosis and fibrosis in chronic hepatitis C. Clin Immunol. 2014;150:149\u201356.","journal-title":"Clin Immunol"},{"issue":"765\u201376","key":"2002_CR31","first-page":"e10","volume":"149","author":"M Sendler","year":"2015","unstructured":"Sendler M, Beyer G, Mahajan UM, et al. Complement component 5 mediates development of Fibrosis, via activation of stellate cells, in 2 mouse models of Chronic Pancreatitis. Gastroenterology. 2015;149(765\u201376):e10.","journal-title":"Gastroenterology"},{"issue":"18","key":"2002_CR32","doi-asserted-by":"publisher","first-page":"10736","DOI":"10.3390\/ijms231810736","volume":"23","author":"F Seidel","year":"2022","unstructured":"Seidel F, Kleemann R, van Duyvenvoorde W, et al. Therapeutic intervention with anti-complement component 5 antibody does not reduce NASH but does attenuate atherosclerosis and MIF concentrations in Ldlr-\/-. Leiden Mice. Int J Mole Sci. 2022;23(18):10736.","journal-title":"Int J Mole Sci"},{"key":"2002_CR33","doi-asserted-by":"publisher","first-page":"E713","DOI":"10.1152\/ajpendo.00194.2007","volume":"293","author":"BM De Taeye","year":"2007","unstructured":"De Taeye BM, Novitskaya T, McGuinness OP, et al. Macrophage TNF-alpha contributes to insulin resistance and hepatic steatosis in diet-induced obesity. Am J Physiol Endocrinol Metab. 2007;293:E713\u201325.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2002_CR34","first-page":"1165","volume":"19","author":"G Schlaf","year":"2004","unstructured":"Schlaf G, Schmitz M, Heine I, et al. Upregulation of fibronectin but not of entactin, collagen IV and smooth muscle actin by anaphylatoxin C5a in rat hepatic stellate cells. Histol Histopathol. 2004;19:1165\u201374.","journal-title":"Histol Histopathol"},{"key":"2002_CR35","first-page":"2336","volume":"30","author":"H Gu","year":"2016","unstructured":"Gu H, Fisher AJ, Mickler EA, et al. Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis. FASEB J Off Pub Fed Am Soc Exp Biol. 2016;30:2336\u201350.","journal-title":"FASEB J Off Pub Fed Am Soc Exp Biol"},{"key":"2002_CR36","doi-asserted-by":"publisher","first-page":"106507","DOI":"10.1016\/j.phrs.2022.106507","volume":"185","author":"S Khanmohammadi","year":"2022","unstructured":"Khanmohammadi S, Kuchay MS. Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease. Pharmacol Res. 2022;185:106507.","journal-title":"Pharmacol Res"},{"key":"2002_CR37","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s00109-014-1170-1","volume":"92","author":"A Wree","year":"2014","unstructured":"Wree A, McGeough MD, Pena CA, et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J Mol Med. 2014;92:1069\u201382.","journal-title":"J Mol Med"},{"key":"2002_CR38","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","volume":"66","author":"AR Mridha","year":"2017","unstructured":"Mridha AR, Wree A, Robertson AAB, et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol. 2017;66:1037\u201346.","journal-title":"J Hepatol"},{"key":"2002_CR39","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1007\/s10753-017-0628-z","volume":"40","author":"C Cai","year":"2017","unstructured":"Cai C, Zhu X, Li P, et al. NLRP3 deletion inhibits the non-alcoholic Steatohepatitis development and inflammation in Kupffer cells induced by Palmitic acid. Inflammation. 2017;40:1875\u201383.","journal-title":"Inflammation"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-023-02002-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-023-02002-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-023-02002-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T09:25:27Z","timestamp":1691832327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-023-02002-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["2002"],"URL":"https:\/\/doi.org\/10.1007\/s00535-023-02002-w","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"assertion":[{"value":"12 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}